Nelipepimut S - Sellas Life Sciences Group

Drug Profile

Nelipepimut S - Sellas Life Sciences Group

Alternative Names: Cancer vaccine E75; Cancer vaccine E75 - Apthera; Cancer vaccine Her2/neu E75 - Apthera; E75; E75 peptide; E75/GM-CSF vaccine; Nelipepimut-S; NeuVax

Latest Information Update: 08 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Henry M. Jackson Foundation for the Advancement of Military Medicine; Uniformed Services University of the Health Sciences; University of Texas M. D. Anderson Cancer Center
  • Developer Galena Biopharma; Sellas Life Sciences Group; University of Texas M. D. Anderson Cancer Center
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase III Breast cancer
  • Preclinical Pancreatic cancer
  • No development reported Bladder cancer; Gastric cancer; Ovarian cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Jun 2018 Additional pre-specified interim analysis efficacy data from a phase IIb trial in Breast cancer released by SELLAS Life Sciences
  • 01 Jun 2018 SELLAS Life Sciences terminates a phase IIb trial in Breast cancer (Combination therapy) in USA because the trial met key clinical development and regulatory consideration (NCT01570036)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top